huperzine a has been researched along with Disease Models, Animal in 31 studies
huperzine A: RN given refers to 5R-(5alpha,9beta,11E)-isomer; structure given in first source
huperzine A : A sesquiterpene alkaloid isolated from a club moss Huperzia serrata that has been shown to exhibit neuroprotective activity. It is also an effective inhibitor of acetylcholinesterase and has attracted interest as a therapeutic candidate for Alzheimer's disease.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Huperzine A (HupA) is an alkaloid isolated from the Chinese folk medicine huperzia serrate, which has possessed diverse pharmacological actions." | 5.40 | The protective effect of huperzine A against hepatic ischemia reperfusion injury in mice. ( Jiang, Q; Yang, J; Yang, Y, 2014) |
| "EAAs sustain seizure activity and induce neuropathology due to over-stimulation of N-methyl-d-aspartate (NMDA) receptors." | 5.35 | [+]-Huperzine A treatment protects against N-methyl-D-aspartate-induced seizure/status epilepticus in rats. ( Coleman, BR; Doctor, BP; Gordon, RK; Nambiar, MP; Oguntayo, SA; Ratcliffe, RH; Shi, X, 2008) |
| "These findings suggested that d-gal causes hearing dysfunction by inflammatory injury of cochlear neurons and that huperzine A could prevent hearing loss by protecting d-gal-induced physical damage of cochlear tissues." | 4.02 | Neuroprotective Effect of Huperzine A on d-Galactose-Induced Hearing Dysfunction. ( Li, C; Shi, S, 2021) |
| "Huperzine A (HupA) is a natural acetylcholinesterase inhibitor (AChEI) with the advantages of high efficiency, selectivity as well as reversibility and can exhibit significant therapeutic effects against certain neurodegenerative diseases." | 1.72 | Huperzine-A Improved Animal Behavior in Cuprizone-Induced Mouse Model by Alleviating Demyelination and Neuroinflammation. ( Sun, J; Wang, D; Wang, J; Wang, Y; Wu, S; Zhang, H, 2022) |
| "Huperzine A (HupA) is a kind of Lycopodium alkaloid with potential disease-modifying qualities that has been reported to protect against β-amyloid (Aβ)-mediated mitochondrial damage in Alzheimer's disease." | 1.51 | ABAD/17β-HSD10 reduction contributes to the protective mechanism of huperzine a on the cerebral mitochondrial function in APP/PS1 mice. ( Chen, Q; Wang, Y; Xiao, X; Zhu, X, 2019) |
| "Huperzine A was administered intraperitoneally to male Wistar Albino rats (220-340 g of body weight) after moderate static clip compression (70 g for 60 s) of the spinal cord at T7 level." | 1.48 | Assessment of the neuroprotective effects of the acetylcholinesterase inhibitor huperzine A in an experimental spinal cord trauma model. ( Altintas, O; Antar, V; Baran, GE; Baran, O; Erdogan, H; Tasdemiroglu, E; Yuceli, S, 2018) |
| "Huperzine A (HupA) is an alkaloid isolated from the Chinese folk medicine huperzia serrate, which has possessed diverse pharmacological actions." | 1.40 | The protective effect of huperzine A against hepatic ischemia reperfusion injury in mice. ( Jiang, Q; Yang, J; Yang, Y, 2014) |
| " Furthermore, subcutaneous administration of Bis-Mep (10, 100 or 1000 ng/kg) significantly reversed the scopolamine-induced memory deficits in a typical bell-shaped dose-response manner." | 1.39 | Bis(9)-(-)-nor-meptazinol as a novel dual-binding AChEI potently ameliorates scopolamine-induced cognitive deficits in mice. ( Chen, HZ; Cui, Y; Ge, XX; Li, J; Liu, T; Qiu, ZB; Wang, H; Xia, Z; Xie, Q; Xu, J; Xu, JR; Zhang, WW, 2013) |
| "Huperzine A (HupA) is a reversible and selective inhibitor of acetylcholinesterase (AChE), and it has multiple targets when used for Alzheimer's disease (AD) therapy." | 1.37 | Huperzine A activates Wnt/β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model. ( Teng, WP; Wang, CY; Wang, SL; Wang, T; Wang, ZY; Xie, JW; Zhao, BL; Zheng, W, 2011) |
| "Huperzine A treatment significantly ameliorated all these phenomena." | 1.36 | Huperzine a improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion. ( Tang, XC; Wang, J; Zhang, HY, 2010) |
| "EAAs sustain seizure activity and induce neuropathology due to over-stimulation of N-methyl-d-aspartate (NMDA) receptors." | 1.35 | [+]-Huperzine A treatment protects against N-methyl-D-aspartate-induced seizure/status epilepticus in rats. ( Coleman, BR; Doctor, BP; Gordon, RK; Nambiar, MP; Oguntayo, SA; Ratcliffe, RH; Shi, X, 2008) |
| "The ability of huperzine A to attenuate memory deficits and neuronal damage after ischemia might be beneficial in cerebrovascular type dementia." | 1.31 | Huperzine A attenuates cognitive deficits and hippocampal neuronal damage after transient global ischemia in gerbils. ( Tang, XC; Zhang, HY; Zhou, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (29.03) | 29.6817 |
| 2010's | 16 (51.61) | 24.3611 |
| 2020's | 6 (19.35) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Zhang, H | 1 |
| Wang, D | 1 |
| Sun, J | 1 |
| Wang, Y | 5 |
| Wu, S | 1 |
| Wang, J | 6 |
| Guo, X | 1 |
| Wu, Y | 1 |
| Wang, Q | 1 |
| Zhang, J | 1 |
| Sheng, X | 1 |
| Zheng, L | 1 |
| Li, C | 1 |
| Shi, S | 1 |
| An, JR | 1 |
| Zhao, YS | 1 |
| Luo, LF | 1 |
| Guan, P | 1 |
| Tan, M | 1 |
| Ji, ES | 1 |
| Riquelme, R | 1 |
| Ruz, F | 1 |
| Mayerhofer, A | 1 |
| Lara, HE | 1 |
| Du, Y | 1 |
| Liang, H | 1 |
| Zhang, L | 1 |
| Fu, F | 2 |
| Turkseven, CH | 1 |
| Buyukakilli, B | 1 |
| Balli, E | 1 |
| Yetkin, D | 1 |
| Erdal, ME | 1 |
| Yilmaz, SG | 1 |
| Sahin, L | 1 |
| Xiao, X | 1 |
| Chen, Q | 1 |
| Zhu, X | 1 |
| Ye, L | 1 |
| Liu, W | 2 |
| Sun, K | 1 |
| Li, Y | 1 |
| He, J | 1 |
| Yu, X | 1 |
| Yu, P | 1 |
| Tian, J | 1 |
| Sui, X | 1 |
| Gao, C | 1 |
| Huang, XT | 2 |
| Qian, ZM | 1 |
| He, X | 1 |
| Gong, Q | 1 |
| Wu, KC | 1 |
| Jiang, LR | 1 |
| Lu, LN | 1 |
| Zhu, ZJ | 1 |
| Zhang, HY | 6 |
| Yung, WH | 1 |
| Ke, Y | 1 |
| Xu, Z | 2 |
| Yang, Y | 1 |
| Yang, J | 1 |
| Jiang, Q | 1 |
| Antar, V | 1 |
| Baran, O | 1 |
| Yuceli, S | 1 |
| Erdogan, H | 1 |
| Altintas, O | 1 |
| Baran, GE | 1 |
| Tasdemiroglu, E | 1 |
| Damar, U | 1 |
| Gersner, R | 1 |
| Johnstone, JT | 1 |
| Schachter, S | 1 |
| Rotenberg, A | 1 |
| Wang, ZF | 1 |
| Tang, XC | 5 |
| Coleman, BR | 1 |
| Ratcliffe, RH | 1 |
| Oguntayo, SA | 1 |
| Shi, X | 1 |
| Doctor, BP | 1 |
| Gordon, RK | 1 |
| Nambiar, MP | 1 |
| Wang, CY | 1 |
| Zheng, W | 1 |
| Wang, T | 1 |
| Xie, JW | 1 |
| Wang, SL | 1 |
| Zhao, BL | 1 |
| Teng, WP | 1 |
| Wang, ZY | 1 |
| Chen, F | 1 |
| Zheng, P | 1 |
| Deng, W | 1 |
| Yuan, J | 1 |
| Peng, B | 1 |
| Wang, R | 1 |
| Zhao, H | 1 |
| Wu, G | 1 |
| Yang, L | 1 |
| Ye, CY | 1 |
| Zhang, X | 2 |
| Lu, L | 1 |
| Liu, S | 1 |
| Ye, W | 1 |
| Wu, J | 1 |
| Liu, T | 1 |
| Xia, Z | 1 |
| Zhang, WW | 1 |
| Xu, JR | 1 |
| Ge, XX | 1 |
| Li, J | 2 |
| Cui, Y | 1 |
| Qiu, ZB | 1 |
| Xu, J | 1 |
| Xie, Q | 1 |
| Wang, H | 1 |
| Chen, HZ | 1 |
| Fan, Y | 1 |
| Hu, J | 1 |
| Yang, Z | 1 |
| Xin, X | 1 |
| Ding, J | 1 |
| Geng, M | 1 |
| Jordá, EG | 1 |
| Verdaguer, E | 1 |
| Jiménez, A | 1 |
| Canudas, AM | 1 |
| Rimbau, V | 1 |
| Camps, P | 1 |
| Muñoz-Torrero, D | 1 |
| Camins, A | 1 |
| Pallàs, M | 1 |
| Zheng, H | 1 |
| Law, SL | 1 |
| Dong So, D | 1 |
| Han, Y | 1 |
| Xue, H | 1 |
| Duysen, EG | 1 |
| Li, B | 1 |
| Darvesh, S | 1 |
| Lockridge, O | 1 |
| Zhou, J | 1 |
| Calon, F | 1 |
| Lim, GP | 1 |
| Morihara, T | 1 |
| Yang, F | 1 |
| Ubeda, O | 1 |
| Salem, N | 1 |
| Frautschy, SA | 1 |
| Cole, GM | 1 |
1 review available for huperzine a and Disease Models, Animal
| Article | Year |
|---|---|
Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.
Topics: Acetylcholine; Alkaloids; Animals; Anti-Inflammatory Agents; Cholinergic Agents; Cholinesterase Inhi | 2009 |
30 other studies available for huperzine a and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Huperzine-A Improved Animal Behavior in Cuprizone-Induced Mouse Model by Alleviating Demyelination and Neuroinflammation.
Topics: Acetylcholinesterase; Animals; Behavior, Animal; Cuprizone; Cytokines; Disease Models, Animal; Encep | 2022 |
Huperzine A injection ameliorates motor and cognitive abnormalities via regulating multiple pathways in a murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholinesterase; Animals; Cognition; Disease Mode | 2023 |
Neuroprotective Effect of Huperzine A on d-Galactose-Induced Hearing Dysfunction.
Topics: Alkaloids; Animals; Cellular Senescence; Cochlea; Disease Models, Animal; Evoked Potentials, Auditor | 2021 |
Huperzine A, reduces brain iron overload and alleviates cognitive deficit in mice exposed to chronic intermittent hypoxia.
Topics: Alkaloids; Animals; Apoptosis; Behavior, Animal; Caspase 3; Cation Transport Proteins; Cognition Dis | 2020 |
Huperzine-A administration recovers rat ovary function after sympathetic stress.
Topics: Acetylcholine; Alkaloids; Animals; Cholinesterase Inhibitors; Cold Temperature; Disease Models, Anim | 2021 |
Administration of Huperzine A exerts antidepressant-like activity in a rat model of post-stroke depression.
Topics: Alkaloids; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Chromatography, High P | 2017 |
Effects of Huperzin-A on the Beta-amyloid accumulation in the brain and skeletal muscle cells of a rat model for Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cholinesterase Inhibitors; Dise | 2017 |
ABAD/17β-HSD10 reduction contributes to the protective mechanism of huperzine a on the cerebral mitochondrial function in APP/PS1 mice.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brai | 2019 |
Preparation and in vitro and in vivo evaluation of HupA PLGA microsphere.
Topics: Acetylcholinesterase; Administration, Oral; Alkaloids; Amyloid beta-Peptides; Animals; Behavior, Ani | 2013 |
Huperzine A ameliorates damage induced by acute myocardial infarction in rats through antioxidant, anti-apoptotic and anti-inflammatory mechanisms.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; bcl-2-Associated X Protein; C | 2014 |
Reducing iron in the brain: a novel pharmacologic mechanism of huperzine A in the treatment of Alzheimer's disease.
Topics: ADAM Proteins; ADAM10 Protein; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precurso | 2014 |
Huperzine A attenuates hepatic ischemia reperfusion injury via anti-oxidative and anti-apoptotic pathways.
Topics: Alanine Transaminase; Alkaloids; Animals; Apoptosis; Aspartate Aminotransferases; bcl-2-Associated X | 2014 |
The protective effect of huperzine A against hepatic ischemia reperfusion injury in mice.
Topics: Alkaloids; Animals; Disease Models, Animal; Inflammation Mediators; Liver; Liver Function Tests; Mal | 2014 |
Assessment of the neuroprotective effects of the acetylcholinesterase inhibitor huperzine A in an experimental spinal cord trauma model.
Topics: Alkaloids; Animals; Apoptosis; Behavior, Animal; Cholinesterase Inhibitors; Disease Models, Animal; | 2018 |
Huperzine A: A promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer's disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetic | 2017 |
Huperzine A exhibits anti-inflammatory and neuroprotective effects in a rat model of transient focal cerebral ischemia.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Ischemic Attack | 2008 |
[+]-Huperzine A treatment protects against N-methyl-D-aspartate-induced seizure/status epilepticus in rats.
Topics: Acetylcholinesterase; Alkaloids; Animals; Body Temperature; Disease Models, Animal; Electroencephalo | 2008 |
Huperzine a improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion.
Topics: Alkaloids; Animals; Carotid Artery Diseases; CD11b Antigen; Cell Hypoxia; Cell- and Tissue-Based The | 2010 |
Huperzine A activates Wnt/β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Prec | 2011 |
Huperzine A ameliorates experimental autoimmune encephalomyelitis via the suppression of T cell-mediated neuronal inflammation in mice.
Topics: Alkaloids; Animals; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Imm | 2012 |
Decreased accumulation of subcellular amyloid-β with improved mitochondrial function mediates the neuroprotective effect of huperzine A.
Topics: Acetylcholinesterase; Adenosine Triphosphate; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; A | 2012 |
Acetylcholinesterase deficiency decreases apoptosis in dopaminergic neurons in the neurotoxin model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcholinesterase; Alk | 2013 |
Bis(9)-(-)-nor-meptazinol as a novel dual-binding AChEI potently ameliorates scopolamine-induced cognitive deficits in mice.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Cogni | 2013 |
Effect of acidic oligosaccharide sugar chain on scopolamine-induced memory impairment in rats and its related mechanisms.
Topics: Adenosine Triphosphatases; Alkaloids; Analysis of Variance; Aniline Compounds; Animals; Behavior, An | 2005 |
(+/-)-huprine Y, (-)-huperzine A and tacrine do not show neuroprotective properties in an apoptotic model of neuronal cytoskeletal alteration.
Topics: Alkaloids; Alzheimer Disease; Aminoquinolines; Animals; Animals, Newborn; Apoptosis; Cerebellum; Cho | 2004 |
Effects of a memory enhancing peptide on cognitive abilities of brain-lesioned mice: additivity with huperzine A and relative potency to tacrine.
Topics: Alkaloids; Animals; Avoidance Learning; Behavior, Animal; Brain Diseases; Cognition Disorders; Disea | 2006 |
Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Topics: Acetylcholine; Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Butyrylcholinesterase; C | 2007 |
Huperzine A attenuates cognitive deficits and hippocampal neuronal damage after transient global ischemia in gerbils.
Topics: Acetylcholinesterase; Administration, Oral; Alkaloids; Animals; Choline O-Acetyltransferase; Cogniti | 2001 |
Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; bcl-Ass | 2005 |